Bronchiectasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Bronchiectasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchiectasis - Drugs In Development, 2022, provides an overview of the Bronchiectasis (Respiratory) pipeline landscape.
Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss and fever. Causes of bronchiectasis include inhaling foreign object, cystic fibrosis, GERD and weakness in immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants and mucolytic agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchiectasis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Bronchiectasis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Bronchiectasis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 7, 7, 1, 8 and 4 respectively.
Bronchiectasis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchiectasis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Bronchiectasis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bronchiectasis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bronchiectasis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bronchiectasis (Respiratory)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bronchiectasis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bronchiectasis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Bronchiectasis – Overview
Bronchiectasis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Bronchiectasis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bronchiectasis – Companies Involved in Therapeutics Development
Armata Pharmaceuticals Inc
BioAegis Therapeutics Inc
Boehringer Ingelheim International GmbH
Chiesi Farmaceutici SpA
Cila Therapeutics
CSL Ltd
Destiny Pharma Plc
Haisco Pharmaceutical Group Co Ltd
Helperby Therapeutics Group Ltd
Insmed Inc
Joincare Pharmaceutical Group Industry Co Ltd
Kamada Pharmaceuticals
Kyowa Kirin Co Ltd
MDI Therapeutics Inc
Metagone Biotech Inc
Novabiotics Ltd
Novartis AG
OrPro Therapeutics Inc
Parion Sciences Inc
PureIMS BV
Renovion Inc
Santhera Pharmaceuticals Holding AG
SolAeroMed Inc
Spexis AG
Suzhou Regend Therapeutics Co Ltd
Therapeutic Systems Research Laboratories Inc
Thirty Respiratory Ltd
Vast Therapeutics Inc
Zambon Co SpA
Bronchiectasis – Drug Profiles
alpha-1 proteinase inhibitor (human) second generation – Drug Profile
APPA-02 – Drug Profile
ascorbic acid – Drug Profile
benralizumab – Drug Profile
BI-1291583 – Drug Profile
BIOC-11 – Drug Profile
brensocatib – Drug Profile
CHF-6333 – Drug Profile
CIL-006 – Drug Profile
CSL-787 – Drug Profile
HSK-31858 – Drug Profile
HY-006 – Drug Profile
icenticaftor – Drug Profile
lonodelestat – Drug Profile
MDI-2517 – Drug Profile
MGS-2525 – Drug Profile
murepavadin – Drug Profile
NCFBE-1 – Drug Profile
NCFBE-2 – Drug Profile
NM-003 – Drug Profile
ORP-100S – Drug Profile
Recombinant Plasma Gelsolin Replacement for Cystic Fibrosis and Bronchiectasis – Drug Profile
REGEND-001 – Drug Profile
REGEND-002 – Drug Profile
REGEND-006 – Drug Profile
S-1226 – Drug Profile
Small Molecules for Bronchiectasis – Drug Profile
sodium nitrite – Drug Profile
tobramycin – Drug Profile
tobramycin + triclosan – Drug Profile
XF-70 – Drug Profile
Bronchiectasis – Dormant Projects
Bronchiectasis – Discontinued Products
Bronchiectasis – Product Development Milestones
Featured News & Press Releases
May 17, 2022: Insmed presents new data on brensocatib at American Thoracic Society 2022 International Conference
Apr 07, 2022: Renovion provides regulatory update and initiation of clinical program in non-CF bronchiectasis
Feb 22, 2022: Armata Pharmaceuticals announces clearance of investigational new drug application to initiate phase 2 clinical trial of AP-PA02 in non-cystic fibrosis bronchiectasis
Sep 21, 2021: Renovion and the COPD Foundation launch COPD and bronchiectasis development partnership to address unmet patient need
Dec 02, 2020: Insmed announces initiation of phase 3 ASPEN study of brensocatib in patients with bronchiectasis
Nov 15, 2020: SolAeroMed provides update on Phase II trial of S1226
Nov 13, 2020: Insmed receives priority medicines (PRIME) designation from European Medicines Agency (EMA) for Brensocatib in patients with non-cystic fibrosis bronchiectasis (NCFBE)
Sep 30, 2020: Insmed highlights progress across portfolio and outlines growth strategy on brensocatib at R&D Day
Sep 07, 2020: New England Journal of Medicine publishes positive results from phase 2 WILLOW study of Brensocatib in patients with non-cystic fibrosis bronchiectasis
Jun 24, 2020: Positive Results from phase 2 WILLOW study of Brensocatib in patients with non-cystic fibrosis bronchiectasis presented at ATS Virtual Clinical Trials Session
Jun 08, 2020: Insmed receives FDA breakthrough therapy designation for Brensocatib in patients with non-cystic fibrosis bronchiectasis (NCFBE)
May 20, 2020: Insmed to showcase new brensocatib data at American Thoracic Society virtual clinical trials session
Feb 03, 2020: Insmed announces positive top-line results from phase 2 WILLOW study of INS1007 in patients with Non-Cystic Fibrosis Bronchiectasis
Jun 07, 2019: Polyphor presents new in-vivo efficacy and tolerability data for a potential inhaled administration of its lead antibiotic murepavadin at the European Cystic Fibrosis Conference
Oct 12, 2017: Polyphor launches the development of an inhaled formulation of its antibiotic Murepavadin and joins a European consortium of leading hospitals and research institutions
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Bronchiectasis, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Products under Development by Companies, 2022
Table 5: Products under Development by Companies, 2022 (Contd..1)
Table 6: Number of Products by Stage and Target, 2022
Table 7: Number of Products by Stage and Mechanism of Action, 2022
Table 8: Number of Products by Stage and Route of Administration, 2022
Table 9: Number of Products by Stage and Molecule Type, 2022
Table 10: Bronchiectasis – Pipeline by Armata Pharmaceuticals Inc, 2022
Table 11: Bronchiectasis – Pipeline by BioAegis Therapeutics Inc, 2022
Table 12: Bronchiectasis – Pipeline by Boehringer Ingelheim International GmbH, 2022
Table 13: Bronchiectasis – Pipeline by Chiesi Farmaceutici SpA, 2022
Table 14: Bronchiectasis – Pipeline by Cila Therapeutics, 2022
Table 15: Bronchiectasis – Pipeline by CSL Ltd, 2022
Table 16: Bronchiectasis – Pipeline by Destiny Pharma Plc, 2022
Table 17: Bronchiectasis – Pipeline by Haisco Pharmaceutical Group Co Ltd, 2022
Table 18: Bronchiectasis – Pipeline by Helperby Therapeutics Group Ltd, 2022
Table 19: Bronchiectasis – Pipeline by Insmed Inc, 2022
Table 20: Bronchiectasis – Pipeline by Joincare Pharmaceutical Group Industry Co Ltd, 2022
Table 21: Bronchiectasis – Pipeline by Kamada Pharmaceuticals, 2022
Table 22: Bronchiectasis – Pipeline by Kyowa Kirin Co Ltd, 2022
Table 23: Bronchiectasis – Pipeline by MDI Therapeutics Inc, 2022
Table 24: Bronchiectasis – Pipeline by Metagone Biotech Inc, 2022
Table 25: Bronchiectasis – Pipeline by Novabiotics Ltd, 2022
Table 26: Bronchiectasis – Pipeline by Novartis AG, 2022
Table 27: Bronchiectasis – Pipeline by OrPro Therapeutics Inc, 2022
Table 28: Bronchiectasis – Pipeline by Parion Sciences Inc, 2022
Table 29: Bronchiectasis – Pipeline by PureIMS BV, 2022
Table 30: Bronchiectasis – Pipeline by Renovion Inc, 2022
Table 31: Bronchiectasis – Pipeline by Santhera Pharmaceuticals Holding AG, 2022
Table 32: Bronchiectasis – Pipeline by SolAeroMed Inc, 2022
Table 33: Bronchiectasis – Pipeline by Spexis AG, 2022
Table 34: Bronchiectasis – Pipeline by Suzhou Regend Therapeutics Co Ltd, 2022
Table 35: Bronchiectasis – Pipeline by Therapeutic Systems Research Laboratories Inc, 2022
Table 36: Bronchiectasis – Pipeline by Thirty Respiratory Ltd, 2022
Table 37: Bronchiectasis – Pipeline by Vast Therapeutics Inc, 2022
Table 38: Bronchiectasis – Pipeline by Zambon Co SpA, 2022
Table 39: Bronchiectasis – Dormant Projects, 2022
Table 40: Bronchiectasis – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Bronchiectasis, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Top 10 Targets, 2022
Figure 4: Number of Products by Stage and Top 10 Targets, 2022
Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Top 10 Routes of Administration, 2022
Figure 9: Number of Products by Molecule Types, 2022
Figure 10: Number of Products by Stage and Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings